All In Biotech

Drug Trial Radar · NCT00601107

A Study to Evaluate the Safety and Effectiveness of Doxercalciferol Capsules in Participants With Moderate to Severe Psoriasis

A Multicenter, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Efficacy and Safety of Doxercalciferol Capsules in the Treatment of Subjects With Moderate to Severe Chronic Plaque Psoriasis

Last checked: Nov 19, 2026Latest source record: May 5, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 111 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

111

Actual

Start

Apr 2008

Primary completion

Feb 2009

Study completion Jun 2009

Sponsor

Lead sponsor
Genzyme, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Jan 25, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to evaluate the safety and effectiveness of an investigational drug called doxercalciferol in participants with moderate to severe chronic plaque psoriasis, in comparison with a placebo ("sugar pill"). All study related care was provided including doctor visits, physical exams, laboratory tests and study medication. Total length of participation was 28 weeks.

Conditions

  • Moderate to Severe Chronic Plaque Psoriasis

Interventions

  • DoxercalciferolDrug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With at Least 50 Percent (%) Reduction in Psoriasis Area Severity Index (PASI) Score at Week 12 or Early TerminationTime frame: Week 12 or Early Termination

Locations

19 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Hot Springs, Arizona

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Irvine, California

  • Site not named

    Santa Monica, California

  • Site not named

    Alpharetta, Georgia

  • Site not named

    Indianapolis, Indiana

  • Site not named

    Andover, Massachusetts

  • Site not named

    Boston, Massachusetts

  • Site not named

    Troy, Michigan

  • Site not named

    West Bloomfield, Michigan

  • Site not named

    St Louis, Missouri

  • Site not named

    East Windsor, New Jersey

  • Site not named

    Albuquerque, New Mexico

  • Site not named

    Stony Brook, New York

  • Site not named

    Greer, South Carolina

  • Site not named

    Nashville, Tennessee

  • Site not named

    San Antonio, Texas

  • Site not named

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.